Comparative Pharmacology
Head-to-head clinical analysis: NAVANE versus PROMAZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAVANE versus PROMAZINE HYDROCHLORIDE.
NAVANE vs PROMAZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thioxanthene neuroleptic; blocks postsynaptic dopamine D1 and D2 receptors in the brain; also exhibits anticholinergic, alpha-adrenergic blocking, and sedative effects.
Promazine hydrochloride is a phenothiazine antipsychotic that blocks postsynaptic dopamine D2 receptors in the mesolimbic system, as well as histamine H1, alpha-1 adrenergic, and muscarinic cholinergic receptors. It also has moderate serotonin and weak serotonin-dopamine antagonist effects.
Oral: 10-20 mg three times daily; maximum 160 mg/day. IM (acute): 5-10 mg every 4-6 hours; maximum 30 mg/day.
25-50 mg intramuscularly every 4-6 hours as needed. Maximum 150 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 20-24 hours, allowing for once-daily dosing. Steady-state reached in 4-5 days.
Terminal elimination half-life: 12-18 hours; in elderly or hepatic impairment may extend to 30 hours
Primarily hepatic metabolism; approximately 20-30% excreted renally as metabolites, <1% unchanged. Biliary/fecal excretion accounts for ~50% of metabolites.
Primarily renal (approx. 70-80% as metabolites, <1% unchanged); minor biliary/fecal (approx. 15-20%)
Category C
Category C
Antipsychotic, Typical
Antipsychotic